Perpetua Medical AB (publ) (PERP-B.ST)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 2 | 9 | 10 | 10 | 7 | 15 | 20 | - |
| Operating profit | SEK m | 2 | -2 | ||||||
| Net profit | SEK m | -15 | -14 | -19 | -18 | -2 | 2 | - | - |
| EPS reported | SEK | 0.53 | 0.20 | ||||||
| Operating cashflow per share | SEK | -1.17 | -0.52 | ||||||
| Capex per share | SEK | 0.23 | 0.34 | ||||||
| FCF per share | SEK | -1.40 | -0.86 | ||||||
| Free cash flow | SEK m | -7 | -11 | ||||||
| Net debt | SEK m | -4 | -17 | ||||||
| Book value equity | SEK m | 20 | 16 | ||||||
| Book value per share | SEK | 4.24 | 1.88 | ||||||
| Number of shares | m | 4.66 | 8.56 | ||||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 10.00 | 4.18 | ||||||
| P/B LTM | x | 1.25 | 1.54 | ||||||
| P/S LTM | x | 1.70 | 1.26 | ||||||
| P/FCF LTM | x | -3.78 | -2.30 | ||||||
| EV/EBITDA LTM | x | 4.67 | 10.23 | ||||||
| EV/Sales LTM | x | 1.41 | 0.50 | ||||||
| Earnings Yield LTM | % | +10.00% | +23.92% | ||||||
| FCF Yield | % | -26.47% | -43.41% | ||||||
| Quality | |||||||||
| ROE | % | +12.41% | +14.25% | ||||||
| ROIC | % | +3.72% | +0.28% | ||||||
| Operating margin | % | +14.04% | +1.18% | ||||||
| Gross margin | % | +52.20% | +53.54% | ||||||
| FCF/Sales | % | -44.87% | -44.76% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +109.83% | +182.14% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -36.70 | -60.20 | ||||||
| Net Debt/EBITDA | x | -0.95 | -5.47 | ||||||
| EBIT/Net interest | x | 2.91 | 0.24 | ||||||
| Net debt/market cap | % | +0.72% | +0.63% | ||||||
| Net debt/Equity | x | -0.21 | -1.04 | ||||||
| Gross debt/equity | x | 0.01 | 0.01 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Perpetua Medical AB (publ) delivers a range of solutions and products in Sweden specifically tailored for the application and management of injectable medications. Among its principal offerings is DrugLog, a system designed to mitigate errors in pharmacy medication dispensing. Another key product, WasteLog, serves as a device for analyzing and reconciling discarded and returned controlled injectable substances. Additionally, PrepLog, built upon the core technology of DrugLog, integrates with existing prescription or medication management systems to enable the verification of drug preparations. The company, which was established in 2007 and maintains its headquarters in Uppsala, Sweden, officially changed its name to Perpetua Medical AB (publ) in April 2024, having formerly been known as Pharmacolog i Uppsala AB (publ). Perpetua Medical AB (publ) operates as a subsidiary entity of Nolsterby Invest AB.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Perpetua Medical AB (publ) (PERP-B.ST)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Perpetua Medical AB (publ) delivers a range of solutions and products in Sweden specifically tailored for the application and management of injectable medications. Among its principal offerings is DrugLog, a system designed to mitigate errors in pharmacy medication dispensing. Another key product, WasteLog, serves as a device for analyzing and reconciling discarded and returned controlled injectable substances. Additionally, PrepLog, built upon the core technology of DrugLog, integrates with existing prescription or medication management systems to enable the verification of drug preparations. The company, which was established in 2007 and maintains its headquarters in Uppsala, Sweden, officially changed its name to Perpetua Medical AB (publ) in April 2024, having formerly been known as Pharmacolog i Uppsala AB (publ). Perpetua Medical AB (publ) operates as a subsidiary entity of Nolsterby Invest AB.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free